-
Formulation
-
Routes of Administration
-
Bioavailability
-
Rate of Absorption
-
Number of Compartments for Drug Distribution
-
Volume of Distribution (Vd)
-
Extent of Protein Binding
-
Elimination and Clearance (Cl)
-
Elimination Rate Constant (k)
-
Rate of Elimination
-
Half-Life
-
Mean Residence Time
-
Area Under the Curve (AUC)
-
Introduction to First Order Kinetics
-
First Order Kinetics: Amount of Drug in the Body at a Given Time
-
First Order Kinetics: Plasma Drug Concentration
-
First Order Kinetics: Drug Half-Life and Fraction Remaining
-
Calculating a Drug’s Half-Life in a One Compartment Model
-
Estimation of the Initial Drug Concentration in the Two Compartment Model
-
Zero Order Kinetics
-
Accumulation and Steady State
-
Loading Dose
-
Maintenance Dose and the Dosage Interval
-
Therapeutic Index
-
Plasma Drug Level Monitoring
-
Guidelines of Rowland and Tozer for Planning a Multiple Dose Regimen
-
Loading and Maintenance Doses for an Oral Drug
-
Dosing Interval for an Oral Drug
-
Maximum Steady State Concentration for an Oral Drug
-
Minimum Steady State Concentration for an Oral Drug
-
Average Steady State Concentration for an Oral Drug
-
Amount of Drug in the Body After the Nth Dose of an Oral Drug
-
Plasma Drug Concentration for a Bolus Infusion Regimen
-
Loading and Maintenance Doses for a Bolus Infusion Regimen
-
Dosing Interval for a Bolus Infusion Regimen
-
Maximum Steady State Concentration After Bolus Infusions
-
Minimum Steady State Concentration After Bolus Infusions
-
Average Steady State Concentration After Bolus Infusions
-
Plasma Drug Concentration During an Intermittent Infusion
-
Maximum Steady State Concentration During an Intermittent Infusion
-
Minimum Steady State Concentration During an Intermittent Infusion
-
Plasma Drug Concentration During a Continuous Infusion
-
Infusion Rate and Steady State Concentration for a Continuous Infusion
-
Plasma Drug Concentration After Starting a Continuous Infusion Without a Bolus Dose
-
Plasma Drug Concentration After Starting a Continuous Infusion With a Bolus Dose
-
Number of Half-Lives Required for a Drug to Reach a Given Plasma Concentration During a Continuous Infusion Following a Bolus Dose
-
Calculating the Estimated Drug Clearance and Maintenance Dose in Renal Insufficiency
-
Maintenance Dosage Fraction Based on the Fractional Rate Constant
-
Adjusting a Constant Infusion in Renal Insufficiency
-
Determining the Maintenance Dose of an Oral Drug Needed to Achieve a Steady State Concentration in a Patient in Renal Failure
-
Features of a Drug Likely to Be Removed During Renal Dialysis
-
Pregabalin Dose Adjustment for a Patient with Impaired Renal Function
-
Adjusting the Dose of Allopurinol for Renal Function
-
Estimated Salicylate Serum Levels
-
Acetaminophen Serum Levels (Rumach-Matthew Nomogram)
-
Ibuprofen Serum Levels in Overdosage
-
Monitoring a Patient on Chronic Aspirin Therapy
-
Pseudosepsis Syndrome in Salicylate Intoxication
-
Clinical Features of Salicylate Intoxication in a Neonate
-
When to Suspect Salicylate Intoxication in an Elderly Patient
-
Risk Factors of Alander et al for Hepatocellular Injury in a Pediatric Acetaminophen Overdose
-
Nomogram of Sivilotti et al for Predicting Hepatotoxicity Following Acetaminophen Poisoning
-
Risk Factors for Severe Hepatotoxicity in a Patient with Acetaminophen (Paracetamol) Poisoning
-
Treatment Line for a Patient at Increased Risk for Acetaminophen (Paracetamol) Toxicity
-
Recommendations of Anderson et al for a Young Child Who Has Taken an Overdose of Acetaminophen Elixir
-
Amount of Acetaminophen Consumed Daily By a Person Abusing an Over-the-Counter (OTC) or Prescription Medication
-
Calculating the Exposure to Acetaminophen for a Child Given the Concentrated Infant Formula Rather Than the Children's Formula
-
Respiratory Depression Associated with Opioid Analgesia
-
Sedation Associated with Opioid Analgesia
-
Delirium Associated with Opioid Analgesia
-
Genitourinary Problems in Men Associated with Opioid Analgesia
-
Using Naloxone to Reverse Adverse Effects of an Opioid Analgesic
-
Itching (Pruritus) Associated with Opioid Analgesia
-
Clinical Findings of Opioid Toxicity in a Patient Being Treated for Pain
-
Risk Factors for Opioid Toxicity in a Patient Being Treated for Pain
-
Pulmonary Syndromes Complicating Salicylate Therapy
-
Calculating Total Daily Dose by Body Weight
-
Calculating Total Daily Dose by Height
-
Calculating Total Daily Pediatric Dose by Body Surface Area
-
Calculating Total Daily Dose by Age
-
Age Adjustment for Maintenance Dose
-
Calculating Dose Given by Body Weight or BSA
-
Determining Drip Rate for Drug Infusion Using Microtubing
-
Determining the Infusion Rate of Intravenous Solutions in Drops per Minute
-
Preventing Adverse Events Associated with the Use of an Infusion Pump
-
Prevention of Tampering with a Narcotic Infusion Pump
-
Ethanol Intoxication
-
Estimated Blood Ethanol Level from Body Weight and Number of Drinks
-
Blood Ethanol Levels and the Diagnosis of Alcohol Abuse
-
Urine Ethanol Levels
-
Blood Alcohol Estimation from Osmolal Gap
-
The AUDIT Clinical Procedure to Evaluate Patients for Harmful Effects of Alcohol Use
-
The Alcohol Symptom Checklist of Teplin and Lutz
-
Measurement of Breath Alcohol
-
Disulfiram-Like Reaction to Alcohol Ingestion (Antabuse Reaction, Acetaldehyde Syndrome
-
Equation of Vogel et al for Evaluating Ethanol Intoxication in Children
-
Alcohol-Induced Hangover Symptoms of Pittler et al
-
Alcohol-Induced Hangover Symptom Survey of Wiese et al
-
Criteria of Wiese et al for Alcohol-Induced Hangover
-
Predicting the Likelihood of a Hangover Based on the Amount and Type of Alcohol Intake
-
Estimation of a Person's Alcohol Intake Over Several Years
-
Evaluating a Fatal Ethanol Overdose Using Widmark's Equation and the Ethanol Concentration in Blood and Urine
-
Fatal Flaws in an Alcohol Screening Test Performed As a Department of Transportation (DOT) Regulated Test
-
Fatal Flaws in an Alcohol Confirmatory Test Performed As a Department of Transportation (DOT) Regulated Test
-
Clinical Findings of Alcohol Intoxication in a Young Child
-
Horizontal Gaze Nystagmus Sobriety Test of Good and Augsburger
-
Walk and Turn Test for Estimating Sobriety
-
Combining Results of the Horizontal Gaze Nystagmus and the Walk and Turn Tests
-
One Leg Stand Test for Field Sobriety Testing
-
Reciting the Alphabet in Field Sobriety Testing
-
Finger-to-Nose Test in Field Sobriety Testing
-
Ratio of Urinary 5-Hydroxytryptophol to 5-Hydroxyindoleacetic Acid (5-HTOL to 5-HIAA Ratio) to Determine Ethanol Ingestion or Postmortem Ethanol Production
-
Findings Suggesting In Vitro Ethanol Production in Blood, Tissue or Urine
-
Complications Associated with Ingestion of Pruno (Prison Wine)
-
Complications Associated with Ingestion of Moonshine
-
Beer or Cider Potomania
-
Method of Forrest for Estimating Widmark's Factor in a Patient
-
Equation of Wagner et al for Estimating the Amount of Alcohol Ingested from a Single Blood Alcohol Concentration
-
Risk Factors for Lead or Iron Poisoning Associated with Homemade Alcohol (Including Sapa of Ancient Rome)
-
Handling of a Patient with "Shy Lung" During Alcohol Breath Testing
-
Adverse Effects Associated with Ingesting a "Substitute" Alcohol
-
Specimen Collection for Urine Drug Testing
-
Substance Abuse and Mental Health Services Administration (SAMHSA) Definitions for Validity of a Urine Specimen
-
Urine Excretion of Benzoylecgonine Following Cocaine Use
-
Identification of Heroin Use With Hair Analysis
-
Duration of Detectability of Drugs of Abuse in the Urine
-
6-Acetylmorphine and the Ratio of Morphine to Codeine in the Evaluation of a Patient for Heroin Use
-
Significance of a Negative Urine Drug Screen for Opiates in a Person with a Prescription for Narcotic Analgesics
-
Evaluation of Urinary Opiate Levels After Ingestion of a Poppy Seed Product
-
Handling the Patient Unable to Provide Sufficient Urine for Testing (Shy Bladder Syndrome)
-
Requirements for a Collector of Urine Specimens Submitted for DOT Drug Testing
-
Fatal Flaws in Urine Drug Testing
-
Criteria for Refusal to Take a Department of Transportation (DOT) Drug Test
-
Indications for a Directly Observed Urine Specimen Collection for Drug Testing
-
Reporting the Results of a Urine Drug Test
-
Performing a Physical Examination on a Donor with a Positive Test for Opiates
-
When to Consider Collection of an Alternative Specimen for Drug Testing
-
Findings on Urine Drug Testing in a Patient Using a Vicks Vapor Inhaler
-
Criteria for Reasonable Suspicion of an Employee Being Under the Influence of Drugs or Alcohol
-
Evaluation of an Employee with a Positive Urine Test for Marijuana Who Claims Hemp Food Consumption
-
Correctable Flaws in Drug and Alcohol Testing
-
When to Redesignate the Specimen Bottles of a Split Specimen Collection
-
Identification of the Donor for a Drug or Alcohol Test
-
Situations When a Medical Review Officer (MRO) May Change a Verified Result
-
Actions by the Medical Review Officer (MRO) That Are Prohibited During a Drug Test Result Verification
-
Review of Negative Drug Test Results by the Medical Review Officer (MRO)
-
Validity Tests to Perform on Oral Fluid Used in Testing for Drugs of Abuse
-
Validity Tests to Perform on Sweat Used in Testing for Drugs of Abuse
-
Validity Tests to Perform on Hair Used in Testing for Drugs of Abuse
-
Legal Problems That May Arise When Testing for Drugs of Abuse
-
Reporting Results of a Double Specimen Collection During a Single Testing Event (Immediate Directly Observed Collection)
-
Evaluation of a Patient for Concurrent Use of Cocaine and Alcohol Including Measurement of Cocaethylene
-
Submission of Blind Quality Control Samples by an Employer to a Drug Testing Laboratory
-
World Anti-Doping Agency (WADA) Formula for Normalizing a Urine Drug Concentration Based on the Specific Gravity
-
Determining the Minimum Number of Safety-Sensitive Workers Who Need To Be Randomly Tested To Meet the Department of Transportation (DOT) Requirements
-
Selecting a Worker or Donor at Random to Screen for Drugs of Abuse, Method 1
-
Urine Marijuana Metabolite to Creatinine Ratio of Huestis and Cone for Identifying New Use
-
False Positive Adulterant Tests for pH or Nitrite Associated with a Urinary Tract Infection
-
False Positive Immunoassay for Tetrahydrocannabinol (THC) in a Patient Being Treated with Pantoprazole or Other Proton Pump Inhibitor
-
Measuring Drugs of Abuse in Finger or Toe Nails
-
Selecting a Worker or Donor at Random to Screen for Drugs of Abuse, Method 2
-
Detecting Urinary 11-nor-delta9-tetrahydrocannabivarin-9-carboxylic Acid to Identify Marijuana Use in a Patient Taking Marinol
-
Why to Identify the Specific Opiate Causing a Positive Urine Drug Test
-
Causes of a False Positive Screening Urine Drug Test
-
Causes of a Negative Screening Urine Drug Test
-
Positive Urine Screening Test for Benzodiazepine or THC in an HIV-Positive Patient Taking Efavirenz
-
Unexplained Methamphetamine and Amphetamine in a Sample Due to Benzamphetamine (Didrex), Famprofazone or Other "Precursor" Drug
-
Adjusting a Urine Drug or Chemical Level in Urine for the Specific Gravity of the Sample
-
In Vitro Formation or Degradation of 6-Acetyl Morphine (6-AM)
-
Testing for EDDP in a Patient Receiving Methadone
-
Opioid Process Impurities in the Manufacture of an Opioid Analgesic
-
Ratio of Urine Concentrations of Hydromorphone to Morphine
-
False Positive Opiate Immunoassay Associated with Naloxone
-
Non-Negative Test Results
-
Collection of Hair for Drug Testing
-
Indications to Perform a Complete Analysis of a Drug of Abuse
-
The Clinical Institute Withdrawal Assessment (CIWA-A) for Patients in Alcohol Withdrawal
-
The Benzodiazepine Withdrawal Scale (CIWA-B)
-
Subjective Scoring Index for Opiate Withdrawal during Naloxone Therapy
-
Neonatal Drug Withdrawal Scoring System of Lipsitz
-
Scoring System of Finnegan et al for the Neonatal Abstinence Syndrome
-
Neonatal Withdrawal Inventory
-
Self-Rating Scale for Barbiturate-Benzodiazepine Withdrawal
-
The Moro Scale Score in Neonatal Narcotic Withdrawal
-
The Amphetamine Withdrawal Questionnaire (AWQ)
-
The Clinical Institute Narcotic Assessment (CINA) Scale for Withdrawal Symptoms
-
Grades of Fultz and Senay for Opiate Withdrawal
-
Grading Delirium Tremens (DTs) During Ethanol Withdrawal
-
Indications of Fiellin et al for Detoxification of an Alcoholic as an Inpatient
-
Clinical Findings of Tenenbein et al for Neonatal Withdrawal Associated with Maternal Volatile Substance Abuse
-
Indications of Ritson for Referral of an Alcoholic for Detoxification (Inpatient or Other Specialized Service)
-
Clinical Findings of Sanz et al for Neonatal Withdrawal Associated with Maternal Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
-
Clinical Signs of Methcathinone Withdrawal
-
Neonatal Withdrawal Symptoms Following Maternal Phencyclidine (PCP) Abuse During Pregnancy
-
Clinical Signs of Caffeine Withdrawal
-
Clinical Signs of Dyer et al for Gamma-Hydroxybutyric Acid (GHB) Withdrawal
-
Clinical Findings of Withdrawal from Anabolic Steroids
-
Risk Factors of Lukan et al for Delirium Tremens Developing in an Intoxicated Trauma Patient
-
Clinical Features of Haney et al for Marijuana Withdrawal
-
Clinical Features of Paraldehyde Withdrawal
-
Clinical Features of Meprobamate or Carisoprodol Withdrawal Syndrome
-
Clinical Features of Gabapentin Withdrawal Syndrome
-
Symptoms Score of Judson et al for Opioid Dependence Following Parenteral Administration of Naloxone
-
Sophia Observation withdrawal Symptom scale (SOS) for Opioid or Benzodiazepine Withdrawal in a Pediatric Patient
-
Scopolamine Withdrawal
-
Monoamine Oxidase Inhibitor (MAOI) Withdrawal
-
Antipsychotic Medication (Neuroleptic) Discontinuation Syndrome
-
Withdrawal Syndrome Associated with Discontinuation of Intrathecal Baclofen Therapy
-
Placental Score of Domenici et al for Identifying a Neonate at Risk for Severe Withdrawal Reaction
-
Screening a Trauma Patient for Risk of Delirium Tremens Using the AST and MCV
-
Adverse Effects of Abrupt Beta-Blocker Withdrawal
-
Discontinuation or Post-Removal Symptoms of Scopolamine or Other Antimuscarinic Agents
-
Ruxolitinib Withdrawal Syndrome (Ruxolitinib Discontinuation Syndrome)
-
Grading Depressant Drug Coma
-
Accumulative Prognostic Index in Patients with Depressant Intoxication
-
Intoxication Score in Short Acting Barbiturate Overdosage
-
Clinical Prediction Rule of Christenson et al for Early Discharge of Patients After Presumed Opioid Overdosage
-
EEG Changes of Haider et al in Sedative Overdosage and Coma
-
Risk Factors for Death Following Initiation of Methadone Maintenance Therapy
-
Clinical Findings in Phencyclidine (PCP) Intoxication
-
Clinical Findings in Methcathinone Intoxication
-
Clinical Findings in Gamma-Hydroxybutyric Acid (GHB) Intoxication
-
Clinical Findings in Dextromethorphan Intoxication
-
Clinical Findings in LSD (d-Lysergic Acid Diethylamide) Intoxication
-
Clinical Findings in an Intoxication with a Piperazine Derivative (Benzylpiperazine or Trifluoromethylphenylpiperazine)
-
Clinical Findings in an Intoxication with 4-Bromo-2,5-DMPEA (4-Bromo-2,5-Dimethoxyphenethylamine)
-
Clinical Findings in Ketamine Intoxication
-
Clinical Findings in MDMA (3,4-Methylenedioxymethamphetamine, Ecstasy) Intoxication
-
Clinical Findings in Flunitrazepam (Rohypnol) Intoxication
-
Clinical Findings in 4-Methylthioamphetamine (4-MTA) Intoxication
-
Clinical Findings in Methamphetamine Intoxication
-
Clinical Findings in Cocaine Intoxication
-
Clinical Findings of Cocaine or Amphetamine Abuse in a Pregnant Woman
-
Risk Factors for an Accidental Heroin Overdose
-
Recommendations of Desai et al for Handling a Patient Who Is Addicted to an Over-the-Counter (OTC) Medication
-
Clinical Features of a Caffeine Overdose
-
Clinical Findings in Marijuana Intoxication
-
Cocaine "Washed-Out" Syndrome
-
Risk Factors for Seizures in a Person Who Abuses Cocaine
-
Causes of Abdominal Pain and Peritonitis in a Person Who Abuses Cocaine
-
Ginseng Abuse Syndrome
-
Complications of Roszler et al for Intravenous Drug Injections Into the Groin
-
Clinical Features of Paraldehyde Abuse
-
Clinical Features of Chloral Hydrate
-
Heavy Metal Poisoning Associated with an Improperly Made Drug of Abuse
-
Grading the Severity of Intoxication with a CNS Stimulant
-
Ocular Changes in Drug Misuse
-
Clinical Findings in a Patient Abusing Nonpharmaceutical Fentanyl (NPF)
-
Clinical Findings in Intoxication with a Tryptamine
-
Hazards of Other Medications Ingested During the Abuse of an Over-the-Counter (OTC) Medication
-
Parkinsonism from Exposure to MPTP Contaminating a Synthetic Meperidine Analogue
-
Noncardiogenic Pulmonary Edema (NCPE) Associated with a Heroin or Opiate Overdose
-
Control of Chronic Skin Ulcerations Secondary to Injections of Abused Drugs
-
Urinary Tract Changes Associated with Ketamine Abuse in Hong Kong
-
Status Asthmaticus Triggered By Heroin Inhalation
-
Transient Ischemic Colitis Following Use of Amphetamine or Cocaine
-
Clinical Findings in Gamma-Butyrolactone (GBL) or 1,4-Butanediol (1,4-BD) Intoxication
-
Excited Delirium Associated with Cocaine Intoxication
-
Signs and Symptoms of Buprenorphine Misuse
-
Flumazenil Therapy for Reversal of Benzodiazepine Effects
-
Signs and Symptoms of Carisoprodol Misuse
-
Synthetic Cannabinoids (Spice Drugs, K2, JWH-018, JWH-073, CP 47497, HU-210)
-
Clinical Features of Mephedrone Intoxication (Bath Salts)
-
Cannabis Hyperemesis Syndrome (CHS)
-
Pulmonary Talcosis Following Intravenous Abuse of an Oral Medication
-
Toxic Leukoencephalopathy Following Heroin Smoking (Heroin Vapor Abuse, "Chasing the Dragon")
-
Differential Diagnosis of Dyspnea in a Person Who Abuses Drugs
-
Hyponatremia Associated with MDMA (Ecstasy) Intoxication
-
Spectrum of Acute Renal Injury Associated with MDMA (Ecstasy) or Other Party Drugs
-
Importance of a Complete Medical Examination in a Patient with a Suspected Drug Overdose
-
"Parachuting" an Oral Drug of Abuse
-
Respiratory Depression Due to Co-Ingestion of Two or More CNS Depressants (Ethanol and Benzodiazepines, Opiates and Muscle Relaxants, Other)
-
Pneumomediastinum and Cervical Soft Tissue Emphysema Associated with Drug Abuse
-
Ways That a Fentanyl Transdermal Patch May Be Abused
-
Monitoring Drugs Using the Concentration in Saliva
-
When to Measure a Drug Metabolite
-
Risk of Noncompliance in Use of Medications
-
The Pill Identification Test for Assessing Compliance with Therapy
-
Self-Reported Medication Adherence Scale of Morisky et al
-
Adherence Score of Duong et al for Patients on Antiretroviral Therapy
-
Simplified Medication Adherence Questionnaire (SMAQ)
-
Modified Questionnaire of Duong et al to Identify Reasons for Missing Medication Doses
-
Method of Ho et al for Grading Adherence to Antiretroviral Therapy
-
Rating of Medication Influences (ROMI) Scale of Weiden et al for Compliance with Drug Therapy in Schizophrenia
-
Method of Kent et al for Improving Adherence in HIV-Infected Patients
-
Overcompliance with a Medication
-
Reasons Listed by Fuhrer et al for Noncompliance by Patients with Pressure Ulcers
-
Findings Suggesting Noncompliance in the Use of Medications
-
Factors Identified by George et al Affecting Adherence in a Patient with Chronic Obstructive Pulmonary Disease (COPD)
-
Directly Observed Therapy (DOT)
-
Enablers and Incentives in a Patient-Centered Treatment Strategy to Increase Patient Compliance with a Long-Term Therapeutic Regimen
-
Risk Factors for Noncompliance in Thienopyridine Therapy by a Cardiac Patient with a Drug-Eluting Stent
-
Factors of Walker et al Affecting Adherence to Medications for Prevention of Type 2 Diabetes
-
Factors of Moynihan et al Affecting the Adherence of a Male with Testicular Cancer to Medical Advice
-
Model of Chisholm-Burns et al for Predicting the Adherence Rate of a Renal Transplant Recipient to Immunosuppressant Therapy
-
Risk Factors of D'Inca et al for Nonadherence to Drug Therapy in a Patient with Inflammatory Bowel Disease (IBD)
-
Risk Factors of Copp et al for Compliance with Antibiotic Prophylaxis for Vesicoureteral Reflux
-
Predictors of Shah et al for a Patient Filling the First Prescription ("First-Fill") for an Antihypertensive Medication
-
Predictors of Solomon et al for a Woman with Osteoporosis Showing Low Adherence to Bone Protective Medications
-
Factors of Zaghloul et al Affecting Compliance with Therapy for Psoriasis
-
Factors of Myat et al Affecting Compliance with Antihypertensive Therapy
-
Factors Affecting Adherence with Iron Chelation Therapy (ICT)
-
Multicentre Study of Poisoning in Children (MSPC) Score
-
Poisoning Severity Score in Acute Poisoning
-
Estimating the Amount of Agents Ingested in an Acute Poisoning
-
Modified Oklahoma Poisoning Questionnaire (OPQ) for Predicting Recurrent Accidental Poisoning in a Young Child
-
Indications for Digoxin Blood Level Monitoring
-
Reversing Digoxin Overdosage with Fab Antibody Fragments
-
Algorithm of Salhanick and Shannon for Management of Acute Poisoning with a Calcium Channel Antagonist
-
Cinchomism Associated with Quinidine or Quinine Therapy
-
Risk Factors for Digitalis Toxicity
-
Risk Factors for Calcium Channel Blocking Agent Toxicity
-
Clinical Findings with a Beta-Blocker Intoxication
-
Monitoring of N-Acetylprocainamide (NAPA) in a Patient Being Treated with Procainamide
-
Equation of Nicholson et al for Prescribing Digoxin
-
Simple Score of Nicholson et al for Prescribing Digoxin
-
Clinical Findings Suggesting the Possibility of a Surreptitiously Administered Sedative
-
Steps to Avoid Surreptitious Sedative Ingestion ("Being Slipped a Mickey")
-
Hangover Symptoms Following the Use of a Benzodiazepine as a Hypnotic Drug
-
Risk Factors for Hangover Symptoms Following the Use of a Benzodiazepine as a Hypnotic Drug
-
Evaluation of a Worker with a Post-Accident Drug Test Showing the Presence of a Benzodiazepine
-
Failure to Recall an Activity After Use of a Soporific Benzodiazepine (Temazepam, Triazolam)
-
Score of Naranjo et al for Estimating the Probability of an Adverse Drug Reaction in a Patient
-
French System for Monitoring Unexpected or Toxic Drug Reactions (UTDR)
-
Identifying Elderly Patients with Risk Factors for Adverse Drug Reactions
-
Risk Factors of Field et al Associated with Adverse Drug Reactions in Nursing Home Residents
-
Algorithm Used by the FDA Division of Drug Experience to Evaluate the Causal Relationship in an Adverse Drug Reaction
-
Managing Common Adverse Reactions to alpha-Interferon
-
Findings of Trontell Suggestive of a Possible Adverse Drug Reaction
-
Risk Model of McElnay et al for Adverse Drug Events in an Elderly Patient
-
Modified Criteria of Schumrock and Thornton for Preventability of an Adverse Drug Reaction (ADR)
-
Classification of McDonnell and Jacobs for the Severity of an Adverse Drug Reaction
-
Comorbid Conditions Contributing to Repeat Hospital Admissions for an Adverse Drug Reaction (ADR) in Older Adults
-
Risk Factors of Green et al for Adverse Drug Events in an Elderly Outpatient
-
GerontoNet ADR Risk Score of Onder et al for Determining Risk of Adverse Drug Reactions in a Hospitalized Geriatric Patient
-
WHO Adverse Reaction Terminology (WHO-ART) Classification for Adverse Drug Reactions
-
Seven Deadly Sins of Inman for Reporting Adverse Drug Reactions (ADR)
-
Kinetic Features of a Poison Making Removal Amenable to an Extracorporeal Technique
-
Indications for Extracorporeal Elimination of Salicylate
-
Indications and Contraindications for Whole Bowel Irrigation (WBI)
-
Toxic Agents with Poor Adsorption Onto Activated Charcoal
-
Gastric Lavage
-
Problems Associated With the Use of Ipecac to Induce Emesis
-
Use of Cathartics to Aid in Gut Decontamination
-
Accidental Injection or Extravasation of Vasoconstricting Drugs into Subcutaneous Tissues
-
Reducing the Risk of Improper Intrathecal Drug Injection
-
Risk of Extravasation Injury Associated with an Intravascular Infusion in a Peripheral Vein
-
Risk for Chemical Mediastinitis Associated with Extravasation of Drug from a Central Intravascular Catheter
-
Grading the Severity of Infiltration and Extravasation Injury
-
Clinical Features of an Allergic Flare Reaction to Intravenous Infusion of a Drug
-
Preventing Complications Associated with Intramuscular (IM) Injections
-
Techniques of Gault for Prevention of Extravasation Injury
-
Criteria of Spenny et al for the Compartment Syndrome Following Extravasation Injury
-
Changes in Subcutaneous Fat at Sites of Insulin Injection (Lipoatrophy or Lipohypertrophy)
-
Complications Associated with Intramuscular Injections
-
Risk Factors for Subcutaneous Abscess or Cellulitis Associated with Continuous Insulin Infusion with an Insulin Pump
-
Cosmetic Skin Changes at the Site of Repeated Subcutaneous Injections
-
Risk Factors for Unintentional Intra-Arterial Drug Injection
-
Clinical Findings Following Unintentional Intra-Arterial Drug Injection
-
Indicators for Identifying an Unintentional Intra-Arterial Drug Infusion
-
Factors of Chan et al That Determine Whether an Intramuscular Injection into the Buttocks Reaches Muscle or Fat
-
Recommendations of Grissinger for Reducing the Risk of Serious Complications Associated with Intravascular Injection of a Caustic Drug
-
Traumatic Neuritis of the Sciatic Nerve Following Intramuscular (IM) Injection
-
Local Injection Site Reaction to Subcutaneous Administration of Etanercept
-
Nicolau's Syndrome (Embolia Cutis Medicamentosa)
-
Hoigne Syndrome (Pseudo-anaphylaxis, Procaine Psychosis) Following Injection of Procaine Penicillin or Other Drugs
-
Aluminium Granulomata (Aluminum Granulomata) at an Injection Site
-
Central Nervous System Oxygen Toxicity
-
Pulmonary Oxygen Toxicity
-
Clinical Features of the Anticholinergic and Central Anticholinergic Syndromes
-
Screening for Anticholinergic Drug Toxicity Using Intravenous Physostigmine
-
Anticholinergic Risk Scale of Rudolph et al
-
Muscarinic Effects of a Cholinergic Agent
-
Nicotinic Effects of a Cholinergic Agent
-
Criteria for Chelation Therapy in Patients with Iron Intoxication
-
Determining the Amount of Elemental Iron Ingested
-
Clinical Stages of Iron Intoxication
-
Criteria for Hepatotoxicity Associated with Acute Iron Poisoning
-
Criterion of Yatscoff et al for Discontinuation of Desferoxamine Therapy for Acute Iron Poisoning
-
Desensitization to Asparaginase
-
Clinical Features of the Anticonvulsant (Antiepileptic) Drug Hypersensitivity Syndrome
-
Risk Factors Associated with the Anticonvulsant (Antiepileptic) Drug Hypersensitivity Syndrome
-
Questions of Lorenz et al for Determining If a Drug Has Caused a Release of Histamine
-
Criteria of Lorenz et al for Histamine Release Response Associated with a Drug
-
Classification of Lorenz et al for the Severity of a Drug-Induced Histamine Release Response
-
Recognition of an Allergic Reaction to an Antiretroviral Medication
-
Aspirin Triad Syndrome
-
Hypersensitivity Reaction to Paclitaxel (Taxol)
-
Hypersensitivity Reaction to Drugs Formulated with Cremophor EL (Polyethoxylated Castor Oil)
-
Hypersensitivity Reactions to Tartrazine (FD&C Yellow No. 5)
-
Risk Factors of Schindewolf et al for a Delayed Hypersensitivity Type Skin Reaction to Heparin
-
Anaphylactic Response Following Injection of a Corticosteroid
-
Hypersensitivity Reaction to Clopidogrel
-
Risk Factors for a Patient with an Allergy to a Sulfonamide Antibiotic Reacting to a Sulfonamide Nonantibiotic
-
Allergic Reactions to the Coloring Agent E110 (Sunset Yellow FCF)
-
Estimating the Plasma Level of Propylene Glycol from Osmolal Gap
-
Evaluating a Patient for Possible Propylene Glycol Toxicity
-
Adverse Effects of Benzyl Alcohol, Including the Gasping Syndrome in Premature Infants
-
Clinical Features of Acute Camphor Intoxication
-
Cardiotoxicity and Neurotoxicity Following Infusion of 5-Fluorouracil Prepared in Tris Buffer
-
Determining the Isoniazid Acetylation Phenotype Based on Measurement of Urinary Isoniazid and Acetylisoniazid
-
Thiopurine Methyltransferase (TPMT) Activity and Azathioprine Therapy
-
Effect of Polymorphism in Cytochrome P450 (CYP) CYP2D6 on the Metabolism of Oxycodone
-
Indications for Testing a Patient on Warfarin for Polymorphism in Cytochrome P450 (CYP) CYP2C9
-
Identifying a Patient Failing Therapy for Helicobacter pylori Who Should be Phenotyped for CYP2C19
-
Model of Steimer et al for Predicting Adverse Side Effects During Amitriptyline Therapy Based on the CYP2D6 and CYP2C19 Phenotypes
-
Generic Model for Pharmacologic Effects of a Drug Undergoing Metabolism to an Active Compound
-
Identifying Patients at Risk for Irinotecan (Camptosar) Myelotoxicity Based on UGT1A1 Genotype (Including Gilbert's Syndrome)
-
Voriconazole Serum Concentration and CYP2C19 Genotype
-
Methotrexate Toxicity and MTHFR (Methelenetetrahydrofolate Reductase) C677T Polymorphism
-
Identifying a Woman at Risk for Reduced Effectiveness of Tamoxifen Therapy Secondary to Altered Biotransformation
-
Pharmacogenetic Model of Wessels et al for Predicting the Efficacy of Methotrexate Monotherapy at 6 Months in a Patient with Rheumatoid Arthritis
-
Efavirenz Dose Reduction in an HIV-1 Infected Patient Based on CYP2B6 Genotype
-
Nomogram of Schwab et al for Predicting Severe Toxicity Associated with Fluorouracil (5-FU) Therapy
-
HLA Screening to Identify an Asian Patient at Risk for Carbamazepine-Associated Stevens-Johnson Syndrome
-
Impact of CYP2C19 Phenotype on Clopidogrel Response
-
Apoptotic Pharmacogenetic Index (API) of Hlavaty et al for Infliximab Therapy in Crohn's Disease
-
Testing a Patient for Polymorphism in the ABCB1 Gene Prior to Therapy with Docetaxel or Irinotecan
-
Risk Factors of Park et al for Severe Hyperbilirubinemia in an HIV-Positive Patient Receiving Atazanavir
-
Effect of Polymorphism in Cytidine Deaminase on the Pharmacokinetics of Gemcitabine
-
Common Drugs Inducing or Inhibiting Cytochrome P450 Enzymes and the P-Glycoprotein Transporter System
-
Interference By Grapefruit, Cranberry and Other Juices With Drug Metabolism
-
Ratio of Urinary 6-Beta-Hydroxycortisol to Cortisol to Phenotype CYP3A4 Activity
-
Findings Suggestive of a Change in Drug Metabolism (Induction or Inhibition)
-
Differential Diagnosis of Medication Intolerance
-
Criteria of Pinilla-Ilbarz et al for Drug Intolerance
-
Indications for Antiepileptic Drug Monitoring
-
Clinical Features of a Carbamazepine Overdose
-
Equation of Umstead and Neumann for Predicting Free Phenytoin Based on the Serum Albumin in a Cancer Patient
-
The Sheiner-Tozer Equation for Normalizing the Total Serum Phenytoin Concentration in a Patient with Hypoalbuminemia
-
Normalizing the Total Serum Phenytoin Concentration for a Patient with End Stage Renal Disease and Hypoalbuminemia
-
Estimate of Dasgupta et al for Free Phenytoin Concentration
-
Estimating the Volume of Distribution for Phenytoin in a Patient with Hypoalbuminemia
-
Indications for Direct Measurement of the Free (Unbound) Serum Phenytoin Concentration
-
Equation of Coleman et al for Calculating the Free Phenytoin Concentration at 37°C Based on Testing at Room Temperature
-
Model of Allison et al for Estimating Carbamazepine 10,11- Epoxide Concentration in Serum Based on Carbamazepine Levels by 2 Different Immunoassays
-
Equation of May et al for Predicting Unbound Concentration of Phenytoin in a Patient Being Treated with Phenytoin and Valproic Acid
-
Equation of Haidukewych et al for Predicting Unbound Concentration of Phenytoin in a Patient Being Treated with Phenytoin and Valproic Acid
-
Clinical Findings in a Patient with an Overdose of Valproic Acid
-
Administration of L-Carnitine in a Patient with an Overdose of Valproic Acid
-
Risk Factors for Toxicity Associated with Infusions of Sodium Nitroprusside
-
Clinical Findings Suggestive of Cyanide Poisoning
-
Exposures That May Be Associated with Cyanide Poisoning
-
Arteriolization of Venous Blood in Cyanide Poisoning
-
Clinical Features of a Patient Who Abuses Volatile Solvents
-
Techniques Used to Abuse Volatile Inhalants
-
Complications Associated With Volatile Inhalant Abuse
-
Signs and Symptoms of Withdrawal in a Person Who Abuses a Volatile Inhalant
-
Method of Wong et al for Abbreviated Monitoring of Tacrolimus in a Renal Transplant Recipient
-
Method of Weber et al for Abbreviated Monitoring of Mycophenolic Acid (MPA) in a Pediatric Renal Transplant Recipient Receiving Mycophenolate Mofetil (MMF)
-
Method of Filler and Mai for Abbreviated Monitoring of Mycophenolic Acid (MPA) in a Pediatric Renal Transplant Recipient Receiving Mycophenolate Mofetil (MMF)
-
Contraindications to Intravenous Colchicine Administered to a Patient and Indications to Reduce the Dose Administered
-
Clinical Stages of Colchicine Toxicity
-
Ways That a Patient May Develop Colchicine Intoxication
-
Clinical Finding in Isoniazid (INH) Overdosage
-
Administration of Pyridoxine (Vitamin B6) as the Antidote to Isoniazid Intoxication
-
Management of a Patient with an Acute Isoniazid Overdose
-
Risk Factors for Isoniazid Hepatotoxicity
-
Monitoring a Patient for Evidence of Isoniazid Hepatotoxicity
-
Clinical Features of an Overdose with Diphenhydramine or Other H1-Receptor Antagonist
-
Paradoxical Excitation Associated with Diphenhydramine (Benadryl)
-
Sedative Effects of Antihistamine Drugs
-
Signs and Symptoms of Toxicity Associated with Doxylamine Succinate
-
Risk Factors for Theophylline Intoxication
-
Clinical and Laboratory Findings in Theophylline Intoxication
-
Indications of Dawson et al for Admitting a Patient to the Hospital with Theophylline Intoxication
-
Indications of Williams and Erickson for Hemodialysis or Hemoperfusion in a Patient with Theophylline Intoxication
-
Clinical Findings in a Patient Receiving an Overdose of Methylene Blue
-
Serotonin Syndrome Associated with Methylene Blue Therapy
-
Adverse Effects Associated with the Antitussive Agent Benzonatate
-
Inhibition of Organic Anion Transporting Peptide 1A2 (OATP1A2) By Grapefruit and Other Fruit Juices
-
Drugs Associated with Drug-Induced Phospholipidosis (DIP)
-
Diagnostic Features of Drug-Induced Phospholipidosis (DIP)
-
Hepatic Phospholipidosis
-
Impact on Drug Delivery of Placing an Infusing Central Catheter Too Close to a Central Catheter Being Used for Blood Removal
-
Drugs Associated with a False Positive Screen for Phencyclidine (PCP)
-
Withdrawal Syndrome Associated with Discontinuation of Dextromethorphan Abuse
-
Zolpidem Withdrawal Syndrome
-
Toxic Effects of Propoxyphene (Dextropropoxyphene, Darvon, Darvocet)
-
Early Discontinuation of Therapy
-
Predictors of Owusu et al for Tamoxifen Discontinuation in an Older Woman with Estrogen-Receptor Positive Breast Cancer
-
Classification of Tsai et al for the Severity of an Acute Poisoning
-
Score of Du et al for Detecting an Adverse Drug Reaction (ADR) in the Neonatal Intensive Care Unit
-
Risk Factors of Rashed et al for Adverse Drug Reactions in a Hospitalised Child
-
Risk Factors of Kane-Gill et al for Adverse Drug Events (ADE) in a Critically-Ill Patient
-
Adverse Drug Event (ADE) Trigger Tool: Clinical Events
-
Adverse Drug Event (ADE) Trigger Tool: Administration of an Antidote
-
Adverse Drug Event (ADE) Trigger Tool: Laboratory Tests
-
Unsafe Injection Practices
-
Indications for Chelation Therapy for a Transfusion-Dependent Patient with Myelodysplasia and Iron Overload
-
Phenotypes of Cytochrome P450 2D6
-
Risk Factors of Pawasauskas et al for Naloxone Use to Reverse Oversedation or Respiratory Depression in a Hospitalized Patient
-
Impact of Variation in the Aldehyde Dehydrogenase (ALDH2) Gene and Alcohol Use in Japanese and Other Asians
-
Estrogenic Effects Associated with Phytoestrogens in Alcoholic Beverages
-
Congeners in Alcoholic Beverages
-
Alcohol-Induced Pain
-
Acute Alcohol Poisoning
-
Auto-Brewery Syndrome (Colonic Fermentation with Endogenous Ethanol Production)
-
Quetiapine Discontinuation Syndrome
-
Synthetic Cannabinoid Withdrawal Syndrome
-
Risk Factors for Quetiapine Abuse
-
Rachacha Ingestion
-
Treatment Fatigue
-
Adverse Drug Reactions Associated with Breastfeeding
-
Risk Factors of Pedros et al for Being Hospitalized for an Adverse Drug Reaction
-
Clinical Prediction Rule of Sakuma et al for Adverse Drug Events in a Hospitalized Adult Patient
-
Score of Urbina et al for a Drug-Related Problem in a Hospitalized Patient
-
Use of 1% Lidocaine Solution as a Diluent to Reduce Pain After an Intramuscular Injection
-
Extravasation Injury Associated Concentrated Dextrose (50% Dextrose, D50W)
-
Non-Steroidal Anti-Inflammatory Drug (NSAID) Sensitivity (NSAID Intolerance)
-
Allergic Contact Dermatitis Associated with a Cresol Preservative (m-Cresol, Meta-Cresol, Chlorocresol, 4-Chloro-m-Cresol)
-
Allergy to Vitamin B12
-
Multiple Drug Intolerance Syndrome (MDIS, Multiple Drug Allergy Syndrome, Multiple Drug Hypersensitivity Syndrome, MDHS)
-
Methanol Poisoning in Moonshine and the Distillation Fractions (“Cuts”)
-
Meconium, Umbilical Cord and Other Alternative Specimens for Retrospective Detection of Maternal Drug Abuse During Pregnancy
-
Zinc Sulfate as an Adulterant for Urine Drug Testing
-
Clinical Predictors of Lee et al for Delirium Tremens (DTs) in an Alcoholic (Early Warning Score for Delirium Tremens)
-
Clinical Features of Alpha-PVP (Flakka)
-
Loperamide (Imodium) Dependence and Abuse
-
Adverse Effects of the Opiate Krokodil (Desomorphine)
-
Clinical Features of Kratom (Mitragynine, Mitragyna speciosa) Abuse
-
Methoxetamine (MXE) Intoxication and Abuse
-
Different Types of Heroin
-
Risk Factors for Noncompliance in the Use of Eye Drops for the Treatment of Glaucoma
-
Reasons Why a Patient with Overactive Bladder (OAB) May Discontinue Therapy with an Antimuscarinic Drug
-
Risk Assessment Score of Sharif-Askari et al for Predicting the Risk of an Adverse Drug Reaction (ADR) in a Hospitalized Patient with Chronic Kidney Disease (CKD)
-
Leakage of Drug Following Subcutaneous or Intramuscular Injection
-
Medication Wrong Route Administration Error
-
Paradichloobenzene (PDB) Intoxication and Addiction (Mothball Madness)
-
Use of Serum FABP1 Concentrations to Predict Outcome Associated with Acetaminophen-Induced Acute Liver Failure (ALF)
-
CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Admission Model Based on Variables from King's College Criteria
-
CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Admission Model Based on New Variables
-
CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Post-Admission Model Based on Variables from King's College Criteria
-
CART Models of Speiser et al for a Patient with Acetaminophen-Induced Acute Liver Failure: Post-Admission Model Based on New Variables
-
False Positive Urine Adulterant Test for Oxidants Associated with a Urinary Tract Infection (UTI)
-
Coma Cocktail
-
Opiate Overdose or Sudden Death After the Loss of Tolerance During Detoxification or Imprisonment
-
Carfentanil (Carfentanyl, Wildnil)
-
Ultra-Potent Synthetic Cannabinoids and Zombie-Like State (AB-FUBINACA, ADB-PINACA, Other)
-
Bupropion (Zyban) Abuse
-
Algorithm of Kramer et al for Diagnosis of an Adverse Drug Reaction (ADR)
-
Criteria of Mannesse et al for the Diagnosis of an Adverse Drug Reaction (ADR)
-
Risk Factors of Mannesse et al for Hospital Admission Associated with an Adverse Drug Reaction (ADR) in an Elderly Adult
-
Nonadherence Due to Pharmacophobia (Pharmaphobia, Medication Phobia)
-
MARRIED-Cocaine Score for Predicting the Risk of Revisit to the Emergency Department by a Cocaine User
-
Stroke or Embolic Complications of Injecting a Melted Suppository
-
Vasculitis Associated with Drug Abuse
-
Differential Diagnosis of Stroke and Cerebrovascular Events in a Person Who Abuses Drugs
-
Lomotil (Diphenoxylate) Abuse and Dependence
-
Protocol of Howes et al for Determining Adherence to Therapy for Schizophrenia
-
Risk Factors of Manini et al for Adverse Cardiovascular Event (ACVE) During a Drug Overdose
-
Clinical Features of 4-Aminopyridine (4-AP, Dalfampridine) Overdose
-
Acute Lurasidone Overdose
-
Clinical Opiate Withdrawal Scale (COWS) of Wesson and Ling
-
Objective Opiate Withdrawal Scale (OOWS) of Handelsman et al
-
Subjective Opiate Withdrawal Scale (SOWS) of Handelsman et al
-
Alcohol Withdrawal Scale (AWS) of Wetterling et al
-
Model of Palmstierna for Predicting Delirium Tremens During Alcohol Withdrawal
-
Nomogram of Eyer et al for the Risk of Delirium Tremens During Alcohol Withdrawal
-
Nomogram of Eyer et al for the Risk of Seizures During Alcohol Withdrawal
-
Luebeck Alcohol Withdrawal Risk Scale (LARS) of Wetterling et al
-
Drug Testing in a Safety-Sensitive Occupation
-
Criteria for Legal Intoxication
-
Criteria from Rome IV for Cannabinoid Hyperemesis Syndrome (CHS)
-
Hazard Factor (HF) of Litovitz and Manoguerra
-
Complications Associated with a Peripherally-Inserted Central Venous Catheter (PICC)
-
Hypersensitivity Reaction to Cetuximab
-
Anaphylactoid Reactions Following Parenteral Administration of Vitamin K1 (Phytonadione)
-
HLA-B*58:01 Genotype and Allopurinol-Induced Hypersensitivity Reaction (Severe Cutaneous Adverse Drug Reaction, SCAR, DRESS)
-
Chloroquine-Induced Renal Phospholipidosis (Pseudo Fabry Nephropathy)
-
Score of Kolb and Himmelsbach for Opiate Withdrawal (Himmelsbach Scale)
-
Predictors of Hedeland et al for Acetaminophen-Induced Hepatotoxicity in a Pediatric Patient
-
Paracetamol Aminotransferase Product in Acetaminophen Toxicity
-
Predictor of James et al for Low Risk of Acetaminophen Toxicity in a Pediatric Patient
-
Mistakes in Workplace Drug and Alcohol Testing
-
Short Opiate Withdrawal Score (SOWS) of Gossop
-
Neonatal Withdrawal Reaction for 4-Methylcathinone
-
Criteria of Alambyan for Toxic Leukoencephalopathy Associated with Heroin Inhalation ("Chasing the Dragon", CTD)
-
Serum Lactate as a Predictor of Mortality in a Drug Overdose
-
Coma Blisters in a Drug Overdose (Coma Bullae, Barbiturate Blisters)
-
Drug Toxicity in a Nonadherent Patient
-
Repeated or Recurrent Poisoning
-
Adverse Drug Reactions Associated with an Overdose of a Slow or Sustained Release Drug Formulation
-
Indications for Extracorporeal Therapy in Lithium Poisoning
-
Indications for Extracorporeal Therapy in a Patient with Metformin Poisoning
-
Indications of Ghannoum et al for Extracorporeal Therapy for Carbamazepine Poisoning
-
Indications of Ghannoum et al for Extracorporeal Therapy for Theophylline Poisoning
-
Indications of Ghannoum et al for Extracorporeal Therapy for Valproic Acid Poisoning
-
Indications of Mactier et al for Extracorporeal Therapy for Barbiturate Poisoning
-
Indications of Gosselin et al for Extracorporeal Therapy for Acetaminophen Poisoning
-
Indications of Ghannoum et al for Extracorporeal Therapy for Thallium Poisoning
-
Indications of Anseeuw et al for Extracorporeal Therapy for Phenytoin Poisoning
-
Injection Site Reaction to Vitamin K
-
Iron Intoxication from Transcutaneous Absorption
-
Disseminated Intravascular Coagulopathy (DIC) and Waterhouse Friderichsen Syndrome in Colchicine Poisoning
-
Diagnosis of Infection in a Patient with Colchicine Intoxication
-
Cardiac Toxicity in Colchicine Poisoning
-
Drug Interaction Probability Scale (DIPS) of Horn et al
-
Adverse Effects of Telbivudine Therapy for Viral Hepatitis B
-
Predictors of Kahn et al for Mortality in a Patient with Delirium Tremens (DTs)
-
Criteria of Kahn et al for Delirium Tremens (DTs)
-
Limb Amputation Associated with Intravascular Drug Abuse
-
Chemsex
-
Score of Camilleri for the Prediction of Acute Intoxication in a Patient with Altered Mental Status and No History of Alcohol or Drug Ingestion
-
Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Administration of an Antidote
-
Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Laboratory Results and Drug Combinations
-
Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Drug Concentration
-
Signals of Handler et al for a Potential Adverse Drug Reaction (ADR) in a Nursing Home: Activation of a Resident Assessment Protocol (RAP)
-
Predictors of Shively et al for a Severe Outcome in Acute Salicylate Poisoning
-
Acute Hangover Scale of Rohsenow et al
-
Hip Flask Defense After an Accident
-
Hack Impairment Index (HII) Associated with Alcohol Intoxication
-
Diphenhydramine and False-Positive Methadone Results on Urine Drug Screening
-
Adverse Effects of Xylazine
-
Side Effects of Cannabidiol (CBD)
-
Speedball (Powerball)
-
Skin Popping and Muscling
-
Cannabis Concentrate (Dab, Butane Hash Oil, BHO)
-
Ayahuasca
-
n-Ethyl Pentylone (NEP)
-
Hyperthermia Associated with a Drug of Abuse
-
ICU Admission Score of Brandenburg et al for an Intoxicated/Poisoned Patient
-
Factors of Al Dweik et al Affecting Patient Reporting of Adverse Drug Reactions (ADR)
-
Severity Categorization for Pharmaceutical Evaluation (SCOPE) Criteria of Quintana-Barcena et al for Drug-Related Problems (DRP)
-
Extravasation of Intravenous Iron
-
Injection Site Reactions for Targeted and Biological Disease-Modifying Therapeutics
-
Causes of a Cholinergic Crisis
-
Clinical Features of a Cholinergic Crisis
-
Management of a Cholinergic Crisis
-
Guidance of Goldfrank et al for Intravenous Dosing of Naloxone for a Patient with Opioid Overdose
-
Prediction of Alcohol Withdrawal Severity Scale (PAWSS) of Maldonodo et al
-
Applejack Palsy and Hangover
-
Simplified Finnegan Neonatal Abstinence Scoring Tool (FNAST) of Devlin et al
-
Simplified Finnegan Neonatal Abstinence Scoring System (sFNAS) of Pomar et al
-
Adverse Effects Associated with Edible Marijuana (Cannabis, THC)
-
Clenbuterol Toxicity
-
Clinical Features of Propylhexedrine (Benzedrex) Intoxication
-
Adverse Effects of Concurrent Exposure to Cocaine and Lidocaine
-
Intoxication and Addiction to Phenibut (beta-Phenyl-gamma-Aminobutyric Acid, PHB)
-
Cannabis (Marijuana) Tourism
-
Risk Factors for Noncompliance with Oral Iron Replacement Therapy
-
Factors Impacting Adherence to Therapy with Tyrosine Kinase Inhibitors (TKI)
-
Medication Possession Ratio (MPR)
-
Risk Factors of Col et al for Noncompliance-Related Hospital Admission for an Elderly Patient
-
Intravenous Lipid Resuscitation in Drug Overdose
-
Brighton Adverse Drug Reactions Risk (BADRI) Model
-
Clinical Prediction Rule of Hohl et al for Detection of a Significant Adverse Drug Effect in an Emergency Department Patient
-
Pseudoallergic Infusion Reaction to Intravenous Iron
-
Risk Factors for Severe Extravasation Injury in Preterm Neonates
-
Stages of Montgomery et al for Infiltration and Extravasation Injury
-
Complement Activation-Related Pseudoallergy (CARPA)
-
Pyridine Toxicity Associated with Ceftazidime Therapy
-
Clinical Findings Associated with an Overdose of an Atypical Antipsychotic
-
Impact of Cirrhosis on the Metabolism of Morphine
-
Causes of a False-Positive Urine Drug Test for Amphetamines
-
NASCORE (Neonatal Abstinence Score) of Kocherlakota et al
-
Neonatal Withdrawal Reaction Following Maternal Antipsychotic Therapy During Pregnancy
-
Visceral Ischemia Associated with Methamphetamine Use
-
Methamphetamine-Associated Toxic Leukoencephalopathy
-
Tianeptine Abuse and Withdrawal
-
Predictors of Krawczyk et al Death Following a Drug Overdose
-
Bad Trip
-
Adverse Drug Reaction (ADR) Severity Assessment Scale of Hartwig et al
-
Adverse Drug Reaction (ADR) Preventability Assessment of Hartwig et al
-
DoTS (Dosing, Timing, Susceptibility) Classification of Adverse Drug Reactions
-
Risk Factors of Davies et al for Adverse Drug Reactions (ADR) on a Hospitalized Patient
-
Clinical Findings Associated with Phenothiazine Overdose
-
Adverse Effects of Topical Methyl Salicylate Preparations
-
Lactic Acidosis in a Patient with Acetaminophen (Paracetamol) Poisoning
-
Pyroglutamic Acidemia in a Patient with Acetaminophen (Paracetamol) Poisoning
-
Vodka Eyeballing
-
Alcohol Enema (Alcohol-Induced Colitis)
-
Differential Diagnosis of Shock During Alcohol Withdrawal
-
Counterfeit or Fake Ethanol
-
False Positive Ethanol Concentration in an Enzymatic Assay
-
Implicit Bias in Drug Testing of Pregnant Mothers and Neonates
-
Shortened MOTHER Neonatal Abstinence Syndrome (sMNAS-9) of Chervoneva et al
-
MOTHER Neonatal Abstinence Syndrome (MNAS)
-
Risk Factors of Zhao et al for Methamphetamine Withdrawal Symptoms for a Person Who Injects Drugs (PWID)
-
Intoxication with 4-Methylethcathinone (4-MEC)
-
5F-Cumyl Pegaclone (SGT-151)
-
Toxicological Significance Score (TSS)
-
Puffy Hand Syndrome
-
Cannabis/Marijuana-Related Cardiac Arrhythmias
-
Telazol (Tiletamine and Zolazepam, TZ) Toxicity
-
Naloxone-Induced Pulmonary Edema
-
Loperamide (Imodium) Overdose
-
Diabetic Ketoacidosis and Substance Abuse
-
Risk Factors for Nonadherence in an Adult with Self-Neglect
-
Predictors of Lee et al for Low Adherence for Oral 5-Amnosalicylic Acid (5-ASA) in a Patient with Ulcerative Colitis
-
Toxicity Associated with Intravenous Nitroglycerin
-
Clinical Features of a Verapamil Overdose
-
Predictors of Munoz et al for Medication-Associated Altered Mental Status in a Hospitalized Patient
-
Fear of Adverse Drug Reactions
-
Opioid Induced Histamine Release from Mast Cells
-
Clinical Features of an Overdose with Lamotrigine
-
Clinical Features of an Overdose with Hydroxychloroquine
-
Clinical Features of an Overdose with Vilazodone
-
Clinical Features of an Overdose with Tizanidine
-
Adverse Effects of 2,4-Dinitrophenol (2,4-DNP)
-
Adverse Effects of Caffeine or Other Methylxanthines Used for Weight Loss
-
Adverse Effects Associated with an Overdose of the Weight Loss Product Hydroxycut
-
Adverse Effects of the Herbal Weight Loss Agent Garcinia cambogia
-
Ketamine Dependence and Withdrawal
-
Risk Score of Minkowitz et al for Opioid-Related Adverse Drug Events (ORADE) in a Surgical Patient: Model for a Male Patient
-
Risk Score of Minkowitz et al for Opioid-Related Adverse Drug Events (ORADE) in a Surgical Patient: Model for a Female Patient
-
Hospital Observation Upon Reversal (HOUR) Prediction Rule for Naloxone
-
Vanilla Extract Abuse
-
Intoxication from Inhaling Ethanol Vapor
-
False-Positive Drug Screen for Lysergic Acid Diethylamide (LSD)
-
Complex Persistent Benzodiazepine Dependence (CPBD)
-
Protracted Withdrawal Syndrome (Postacute Withdrawal Syndrome, PAWS)
-
Marijuana-Induced Gastroparesis (THC-Induced Gastroparesis)
-
Intoxication with Brorphine
-
Opioid-Associated Amnestic Syndrome (Amnesia)
-
Adverse Effects of Exposure to Cinnamon Oil or Powder
-
Vaping THC Oil
-
Skin Necrosis Associated with Injection of a Drug Containing Xylazine
-
5-APB, 5-MAPB and Other Aminoalkylbenzofuran Derivatives
-
Poisoning Early Warning Score of Martin-Rodriguez et al for an Adult with Acute Poisoning
-
Adverse Drug Effects in an Infant Treated for Patent Ductus Arteriosus (PDA)
-
POSAMINO Criteria for Alcohol-Drug Interactions: Drugs Affected by Any Amount of Alcohol
-
POSAMINO Criteria for Alcohol-Drug Interactions: Drugs Affected by Large Amounts of Alcohol
-
PRODIGY Score of Khanna et al for Prediction of Opioid-Induced Respiratory Depression
-
Benzodiazepine Resistant Alcohol Withdrawal (RAW) Score of Benedict et al
-
Drug Testing in a Chronic Pain Patient Receiving Opioids
-
Iatrogenic Withdrawal Syndrome (IWS) in an Adult in the Intensive Care Unit (ICU)
-
Withdrawal Assessment Tool Version 1 (WAT-1) for Opioid or Benzodiazepine Withdrawal in a Pediatric Patient
-
Heroin Transverse Myelitis (Myelopathy)
-
Rhabdomyolysis Associated with Heroin Abuse
-
Model of Chang et al Predictive of Nonadherence with Once-Daily Glaucoma Medications
-
12-Item Malaysia Medication Adherence Assessment Tool (MyMAAT)
-
New Poisoning Mortality Score (new-PMS) of Han et al
-
Neonatal Adverse Event Severity Scale (NAESS) of Salaets et al
-
Defective CYP2D6 Genotype and Doxepin Poisoning
-
1,1-Dufluoroethane Inhalant Abuse
-
Removal of Fentanyl on Environmental Surfaces
-
Dosage Adjustments to LMW Heparin or Fondaparinux in Renal Insufficiency
-
Hypersensitivity Reactions to Opioids (Histamine Release, Anaphylaxis, Anaphylactoid Reaction)
-
NAlaxone CARdiac Arrest Decision Instruments (NACARDI) in Occult Opioid Overdose with Cardiac Arrest
-
Fentanyl-Induced Rigid Chest Syndrome (FIRCS, Wooden Chest Syndrome)
-
Kudzu (Pueraria) Herbal Remedies for Hangover and Alcohol Abuse
-
Addition of a Drug By the Patient to a Urine Specimen Being Used to Screen for Therapeutic Compliance
-
Norbuprenorphine to Buprenorphine Ratio in a Urine Test for Buprenorphine Use
-
Detection of Heroin Use By Testing for Papaverine and Its Metabolites
-
Delayed Presentation of Neonatal Withdrawal Symptoms in Neonates with Congenital Hypothyroidism
-
Adverse Effects pf Eutylone or Ephylone
-
Complications of Using Marijuana (or Cananbis) Wax or Hash Oil
-
Definition of Edwards and Aronson for Adverse Drug Reactions (ADR)
-
SCoRCH Hypersensitivity Reaction
-
Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Bleeding
-
Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Falls, Collapse or Syncope
-
Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Delirium or Confusion
-
Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Abnormal Laboratory Tests
-
Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Renal Insufficiency and/or Dehydration
-
Trigger Tool of Noorda et al for Adverse Drug Reactions (ADR) in an Elderly Patient with Polypharmacy: Miscellaneous Adverse Effects
-
Extravasation of Concentrated Potassium Chloride Solution
-
Maximum Daily Dose of a Drug Formulation Containing Propylene Glycol
-
Toxigenetic Score of Weisman et al for Methotrexate
-
Adverse Effects of Melatonin, Including Overdosage
-
Rupture of the Urinary Bladder from Binge Drinking
-
Alcohol Intolerance Syndromes Associated with Neoplastic Diseases
-
Prediction Model of Simpson et al for Positive Neonatal Meconium and Urine Drug Tests
-
Neonatal Gabapentin Withdrawal Syndrome
-
Predictors of Mohan et al for Intensive Care for a Patient with Alcohol Withdrawal
-
Post-Acute Withdrawal Syndrome (Protracted Alcohol or Drug Withdrawal)
-
Predictors of Marchand et al for Alcohol Withdrawal Syndrome on Admission to a Trauma Center
-
Risk Factors of Coleman et al for a Patient Leaving Against Medical Advice (AMA) During Alcohol Withdrawal
-
Phenibut Withdrawal
-
Precipitated Opioid Withdrawal
-
Dexmedetomidine Withdrawal
-
Differential Diagnosis of Impaired Vision Associated with Methamphetamine Abuse
-
Predictors of Cohen et al for Opioid Overdose in a Pediatric Patient
-
Methamphetamine-Induced Encephalopathy
-
Clinical Features of Fenethylline (Captagon) Intoxication
-
Scopolamine Poisoning Associated with Illegal Substance Abuse
-
Predictors of Naim et al for Prolonged ICU Stay or Death for a Self-Poisoned Patient
-
Prognostic Model of Nakafero et al for Methotrexate Toxicity in a Patient with an Immunologic Disorder
-
Adverse Inpatient Medication Event Model (AIME) of Falconer et al
-
PADR-EC Score of Nair et al for Predicting Hospitalization for an Adverse Drug Reaction in an Elderly Community-Dwelling Adult
-
Adverse Effects Associated with Syringe Lubricant
-
Cauda Equina Syndrome Due to Intrathecal Drug Injection
-
Algorithm of Kim et al for Management of Computed Tomography Contrast Media Extravasation
-
Implications of CYP2D6 Genotype for a Patient Receiving Tamoxifen
-
CYP2D6 Activity Score of Gaedigk et al
